TRIPLE VERSUS DUAL LIPID-LOWERING THERAPY IN ACUTE CORONARY SYNDROME: THE ES-BEMPEDACS RANDOMIZED CLINICAL TRIAL

Sergio Raposeiras-Roubín, MD, PhD; Emad Abu Assi, MD, PhD; César Jiménez Méndez, MD; Ester Mínguez de la Guía, MD; José Ángel Pérez Rivera, MD, PhD; Marta Marcos Mangas, MD; Ana Ayesta, MD, PhD; Aitor Uribarri, MD, PhD; Pablo Jorge Pérez, MD; Pablo José

The research article published in 'Circulation' investigates the outcomes of a randomized clinical trial aimed at assessing the effectiveness of triple lipid-lowering therapy compared to dual therapy in patients suffering from acute coronary syndrome. The study highlights the importance of achieving optimal LDL cholesterol levels and evaluates the potential benefits of incorporating additional lipid-lowering agents in standard treatment protocols. The results indicate that patients receiving triple therapy experienced greater reductions in LDL cholesterol, which may have implications for clinical practice in managing ACS.